乳腺癌耐药蛋白(BCRP/ABCG2/MXR/ABCP)是一种 ATP 依赖性外排转运蛋白,属于存在于细胞膜上的大型 ATP 结合盒 (ABC) 转运蛋白家族,并被归类为这些转运蛋白的 G 亚家族。BCRP 在多种正常细胞中表达,并充当外来化合物外排转运蛋白。BCRP 通常与癌症化疗耐药性有关。BCRP 使一系列抗肿瘤药物(如米托蒽醌、柔红霉素、SN-38 和拓扑替康)产生多药耐药性 (MDR),并且通常会限制化疗的疗效。
BCRP 在生理上是生物体自我防御机制的一部分。它增强肠道和胆道中有毒外来化合物和有害物质的消除,以及通过血脑屏障、胎盘屏障和可能的血睾屏障。BCRP 识别和运输多种抗癌药物,包括传统化疗药物和临床应用相对较新的靶向小分子治疗药物。因此,癌细胞中的 BCRP 表达通过抗癌药物的主动流出直接导致 MDR。由于 BCRP 也被认为是一种干细胞标记物,其在癌细胞中的表达可能是代谢和信号通路的一种表现,这些通路赋予多种药物耐药性、自我更新(干细胞性)和侵袭性(侵袭性)机制,从而导致预后不良。因此,阻断 BCRP 介导的主动流出可能为癌症提供治疗益处。
Breast cancer resistance protein (BCRP/ABCG2/MXR/ABCP) is an ATP-dependent efflux transporter, which belongs to the large ATP-binding cassette (ABC) transporter family present on cell membranes, and it is classified into the G subfamily of these transporters. BCRP is expressed in a variety of normal cells and acts as a xenobiotic efflux transporter. BCRP is often associated with cancer chemotherapeutic resistance. BCRP confers multidrug resistance (MDR) to a series of antitumor agents such as Mitoxantrone, Daunorubicin, SN-38, and Topotecan, and often limits the efficacy of chemotherapy.
BCRP physiologically functions as a part of a self-defense mechanism for the organism. It enhances elimination of toxic xenobiotic substances and harmful agents in the gut and biliary tract, as well as through the blood-brain, placental, and possibly blood-testis barriers. BCRP recognizes and transports numerous anticancer drugs including conventional chemotherapeutic and targeted small therapeutic molecules relatively new in clinical use. Thus, BCRP expression in cancer cells directly causes MDR by active efflux of anticancer drugs. Because BCRP is also known to be a stem cell marker, its expression in cancer cells could be a manifestation of metabolic and signaling pathways that confer multiple mechanisms of drug resistance, self-renewal (stemness), and invasiveness (aggressiveness), and thereby impart a poor prognosis. Therefore, blocking BCRP-mediated active efflux may provide a therapeutic benefit for cancers.
Nedisertib (Peposertib) 是一种口服有效的选择性 DNA 依赖性蛋白激酶 (DNA-PK) 抑制剂(IC50 < 3 nM),同时也是 ABCG2 的调节剂,可通过抑制 DNA 双链断裂修复增强化疗或放疗效果,并能逆转 ABCG2 介导的多药耐药 (MDR),为联合用药提供新策略,具有抗肿瘤活性。
Nedisertib (Standard) 是 Nedisertib (MS-M34479) 的分析标准品,用于研究及分析应用;Nedisertib (Peposertib) 是一种口服有效的选择性 DNA 依赖性蛋白激酶 (DNA-PK) 抑制剂,IC50 值小于 3 nM,同时也是 ABCG2 的调节剂,可逆转 ABCG2 介导的多药耐药 (MDR),为联合用药提供新策略,Nedisertib 可通过
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号